Xcell Therapeutics Inc.
Research Xcell Therapeutics Inc. (373110.KQ) on Bullrun: market cap KRW 20.22B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker373110.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 20.22B
- Financial periodQ2 2026
- RevenueKRW 1.94B
- Net income-KRW 2.76B
- Free cash flow-KRW 1.76B
- Gross margin-28.4%
Valuation Snapshot
latest market cap is KRW 20.22B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 20.22B | n/a | n/a | n/a |
Dividend history
About Xcell Therapeutics Inc.
Xcell Therapeutics Inc. engages in the development and production of drugs for cell therapy. It offers CellCor, a serum-free chemically defined medium that is used to develop human mesenchymal stem cells. The company also offers XPorT, a platform that aims to develop optimal media from the perspective of the user using a variety of cells. In addition, it develops media for cell culture in various areas of the bioindustry such as cell therapy, gene therapy, exosomes, organoids and bioreactors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Xcell Therapeutics Inc.'s market cap?
Xcell Therapeutics Inc.'s market capitalization is KRW 20.22B.
What does Xcell Therapeutics Inc. do?
Xcell Therapeutics Inc. engages in the development and production of drugs for cell therapy. It offers CellCor, a serum-free chemically defined medium that is used to develop human mesenchymal stem cells. The company also offers XPorT, a platform that aims to develop optimal media from the perspective of the user using a variety of cells. In addition, it develops media for cell culture in various areas of the bioindustry such as cell therapy, gene therapy, exosomes, organoids and bioreactors. Xcell Therapeutics Inc. was founded in 2015 and is based in Seoul, South Korea.